In vivo roles of a patient-derived induced pluripotent stem cell line (HD72-iPSC) in the YAC128 model of huntington's disease

International Journal of Stem Cells

Volumn 7, Issue 1, 2014, Pages 43-47

  Jeon, Iksoo ^a   Choi, Chunggab ^a   Lee, Nayeon ^a   Im, Wooseok ^b   Kim, Manho ^b   Oh, Seung Hun ^a   Park, In Hyun ^c   Kim, Hyun Sook ^a   Song, Jihwan ^a  

^a CHA University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggregate formation; GABAergic neurons; Huntington's disease (HD); Induced pluripotent stem cells (iPSCs); YAC128 transgenic mice

Indexed keywords

EID: 84901648245     PISSN: 20053606     EISSN: 20055447     Source Type: Journal    
DOI: 10.15283/ijsc.2014.7.1.43     Document Type: Article

References (16)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676
2. Okita K, Yamanaka S. Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci 2011;366:2198-2207
3. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ. Disease-specific induced pluripotent stem cells. Cell 2008;134:877-886
4. Kaye JA, Finkbeiner S. Modeling Huntington's disease with induced pluripotent stem cells. Mol Cell Neurosci 2013; 56:50-64
5. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993;72:971-983
6. Walker FO. Huntington's disease. Lancet 2007;369:218-228
7. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990-1993
8. Arrasate M, Finkbeiner S. Protein aggregates in Huntington's disease. Exp Neurol 2012;238:1-11
9. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10:83-98
10. Jeon I, Lee N, Li JY, Park IH, Park KS, Moon J, Shim SH, Choi C, Chang DJ, Kwon J, Oh SH, Shin DA, Kim HS, Do JT, Lee DR, Kim M, Kang KS, Daley GQ, Brundin P, Song J. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells 2012;30:2054-2062
11. Chae JI, Kim DW, Lee N, Jeon YJ, Jeon I, Kwon J, Kim J, Soh Y, Lee DS, Seo KS, Choi NJ, Park BC, Kang SH, Ryu J, Oh SH, Shin DA, Lee DR, Do JT, Park IH, Daley GQ, Song J. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem J 2012;446:359-371
12. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003;12:1555-1567
13. Kawasaki H, Mizuseki K, Nishikawa S, Kaneko S, Kuwana Y, Nakanishi S, Nishikawa SI, Sasai Y. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 2000;28:31-40
14. Im W, Ban J, Lim J, Lee M, Lee ST, Chu K, Kim M. Extracts of adipose derived stem cells slows progression in the R6/2 model of Huntington's disease. PLoS One 2013; 8:e59438
15. An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, Melov S, Ellerby LM. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012;11:253-263
16. HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion- associated phenotypes. Cell Stem Cell 2012;11: 264-278